Lundbeck Set For 'Transformative' Eptinezumab Launch
February 21 PDUFA Date For Migraine Drug
Executive Summary
The Danish drugmaker's four 'strategic brands' – Brintellix, Abilify Maintena, Northera and Rexulti – are selling well. Now the focus is firmly on breaking into the anti-CGRP market with eptinezumab.
You may also be interested in...
Lundbeck Pulled New Growth Levers In Q2
Rexulti launch in agitation associated with Alzheimer’s disease is under way with a branded DTC marketing campaign planned for fall.
Lundbeck’s Vyepti Sales Disappoint But Lower Costs Boost Profitability
Sales for the migraine product were lower in Q4 than consensus forecasts projected, but reduced costs have pushed yearly earnings beyond expectations.
Vyepti Sales Disappoint But Lundbeck Sees Growth From Expanded Infusion Center Network
Key brands saw growth in the first half of 2021 despite the company’s overall revenues falling, mainly due to generic competition for Northera.